Free tool
FAERS Monitor: Bicnu
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 017422 or its brand name (Bicnu, Carmustine). Reports on generic versions are filed under their own applications.
Reports
4,156
Serious
4,089
98% of reports
Hospitalization
1,170
Death reported
1,117
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use510
- febrile neutropenia400
- myelodysplastic syndrome298
- disease progression269
- mucosal inflammation256
- thrombocytopenia232
- pyrexia209
- neutropenia206
- pneumonia199
- drug ineffective197
- acute myeloid leukaemia172
- infection165
- diarrhoea160
- product use in unapproved indication156
- sepsis154
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 84 |
| 2005 | 54 |
| 2006 | 35 |
| 2007 | 73 |
| 2008 | 98 |
| 2009 | 92 |
| 2010 | 69 |
| 2011 | 132 |
| 2012 | 128 |
| 2013 | 84 |
| 2014 | 61 |
| 2015 | 132 |
| 2016 | 102 |
| 2017 | 223 |
| 2018 | 315 |
| 2019 | 336 |
| 2020 | 367 |
| 2021 | 309 |
| 2022 | 280 |
| 2023 | 432 |
| 2024 | 293 |
| 2025 | 229 |
| 2026 | 228 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,003 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| myelodysplastic syndromeSignal | 298 | 106.4 | 95.3 | 30,404 |
| acute myeloid leukaemiaSignal | 172 | 56.5 | 48.7 | 9,219 |
| mucosal inflammationSignal | 256 | 50.0 | 44.3 | 12,131 |
| febrile neutropeniaSignal | 400 | 30.7 | 28.0 | 11,429 |
| disease progressionSignal | 269 | 11.5 | 10.3 | 2,585 |
| thrombocytopeniaSignal | 232 | 10.5 | 9.3 | 1,996 |
| neutropeniaSignal | 206 | 7.7 | 6.7 | 1,196 |
| sepsisSignal | 154 | 7.0 | 6.0 | 788 |
| infectionSignal | 165 | 5.8 | 5.0 | 650 |
| product use in unapproved indicationSignal | 156 | 3.2 | 2.7 | 235 |
| pneumoniaSignal | 199 | 3.1 | 2.7 | 287 |
| pyrexiaSignal | 209 | 3.1 | 2.7 | 292 |
| off label useSignal | 510 | 2.9 | 2.7 | 683 |
| diarrhoea | 160 | 1.3 | 1.1 | 8 |
| drug ineffective | 197 | 0.8 | 0.7 | 16 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.